STCube

STCube CapEx/OCF

The CapEx to Operating Cash Flow Ratio of STCube (052020.KQ) as of Oct 24, 2026 is -4.70 %. In the previous year, CapEx to Operating Cash Flow Ratio was -2.70 % — a change of 73.95% (lower).

CapEx/OCF

-4.70 %

YoY

73.95%

Last updated:

CapEx to Operating Cash Flow Ratio of STCube is 2025 -4.70 % . CapEx to Operating Cash Flow Ratio of STCube was 2024 -2.70 % . It decreases by 73.95% lower compared to the previous year.

The STCube CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
-7.37 KRW
Jan 1, 2019
-588.35 KRW
Jan 1, 2020
-1.77 KRW
Jan 1, 2021
-0.30 KRW
Jan 1, 2022
-1.29 KRW
Jan 1, 2023
-1.16 KRW
Jan 1, 2024
-2.70 KRW
Jan 1, 2025
-4.70 KRW
The STCube CapEx/OCF history
YEARCapEx/OCFYoY
-4.70 %+73.95%
-2.70 %+132.22%
-1.16 %-9.98%
-1.29 %+324.90%
-0.30 %-82.83%
-1.77 %-99.70%
-588.35 %+7,885.22%
-7.37 %+15.58%
-6.37 %-105.79%
110.08 %-238.42%
-79.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

CapEx to Operating Cash Flow Ratio of STCube is -4.70 % in 2025.

CapEx to Operating Cash Flow Ratio of STCube changed from -2.70 % to -4.70 %, representing a 73.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio STCube since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's STCube with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — STCube

All Key Metrics — STCube